Key facts
- It has raised $3.7M; the latest was Seed Round ($3.7M) in Feb 2026.
- Notable investors include Plug and Play Tech Center, University of California, California Life Sciences, Eisai Innovation, Freeflow Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Sift Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Sift Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sift Bio
Developer of next-generation immunomodulators designed to treat cancer and autoimmune diseases. The company uses a combination of machine learning and high-throughput antigen screening to identify and develop therapeutic agents that modulate T-cell responses, enabling researchers to have more precise and effective treatments for a wide range of inflammatory and oncological conditions.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2024
- Employees
- 7
- Website
- siftbio.com/
- Ownership
- Privately Held (backing)
Sift Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sift Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sift Bio in its N-PORT filings yet. We sweep new filings monthly.